Latest Lung Imaging News

Page 1 of 5
Cyclopharm has reported record third-quarter US Technegas revenue of A$1.62 million, with 76% generated by recurring consumable orders. Its installed base and hospital pipeline expanded sharply after new clinical guidelines preferred Technegas when available, while quarterly cash burn fell to A$0.9 million.
Ada Torres
Ada Torres
29 Oct 2026
4DMedical reported a record first quarter, with scan volumes up 61% to 119,672 and unaudited operating revenue rising 66% to $2.3 million. New contracts across the US, Germany and Australia broaden the commercial story, while $242.8 million in cash gives the company room to keep investing.
Victor Sage
Victor Sage
28 Oct 2026
4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.
Ada Torres
Ada Torres
28 Aug 2026
Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.
Ada Torres
Ada Torres
24 Aug 2026
4DMedical has secured a pivotal three-year contract with SimonMed Imaging to deploy its CT:VQ™ lung imaging technology across over 170 US outpatient centres, while FY26 revenue rose 23% to $7.2 million on record scan volumes and global expansion.
Ada Torres
Ada Torres
31 July 2026
Cyclopharm’s Technegas® has been named the preferred ventilation agent in new US lung imaging guidelines, marking the first update in 14 years and potentially accelerating adoption across American hospitals.
Ada Torres
Ada Torres
29 July 2026
Cyclopharm has landed a major US expansion deal with University Hospitals Cleveland, deploying Technegas® across 11 sites simultaneously and boosting its recurring revenue base in the Midwest.
Ada Torres
Ada Torres
15 July 2026
Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.
Ada Torres
Ada Torres
2 July 2026
4DMedical has cleared a major regulatory hurdle with the Therapeutic Goods Administration approving its CT:VQ™ lung imaging software, paving the way for commercial use across Australia and strengthening its global footprint.
Ada Torres
Ada Torres
26 June 2026
4DMedical launches the CLEAR clinical evidence program to accelerate adoption of its CT:VQ™ imaging technology in the US acute pulmonary embolism market, aiming to expand its addressable market to US$3 billion.
Ada Torres
Ada Torres
2 June 2026
4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.
Ada Torres
Ada Torres
1 June 2026
4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.
Ada Torres
Ada Torres
29 May 2026

Browse the archive

Full archive